XML 99 R84.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 17, 2018
Jul. 13, 2017
Aug. 02, 2016
Apr. 18, 2016
Jan. 06, 2016
Dec. 08, 2015
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Sep. 03, 2015
Oct. 31, 2014
Dec. 31, 2011
Jun. 29, 2010
Class of Stock [Line Items]                            
Ordinary shares issuance ADSs 1,200,000,000             1,200,000,000 1,100,000,000          
ADSs offering             54,000,000              
Share price $ 15.42           $ 62.50 $ 15.42            
Proceeds from issuance or sale of equity ads             $ 5,400,000,000              
Proceeds from issuance or sale of equity convertible preferred shares             $ 329,000,000              
Shares transferred to Allergan       100,300,000                    
Share issued due to conversion of convertible preferred shares 70,600,000 70,600,000                        
Convertible preferred stock shares issued upon conversion           337,500 3,375,000              
Convertible preferred shares rate             7.00%              
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs ADSs           $ 329,000,000       $ 329,000,000        
Aggregate Proceeds From Issuance Of Preferred Stock And Preference Stock           $ 3,620,000,000                
Convertible preferred stock terms of conversion   1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262                        
Number of shares exercisable 24,086,000             24,086,000            
Number of shares available for future awards 76,600,000             76,600,000            
Vesting period, description               The vesting period of the outstanding options, RSUs and PSUs is generally from 1 to 4 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for seven years in prior plans and ten years for options granted under the 2010 and 2015 plans described above.            
Company average share price $ 20.92             $ 20.92 $ 25.62          
Total intrinsic value of options exercised during the years                   $ 5,000,000        
Average market price of Teva's ordinary shares during the year                   $ 50.96        
Total unrecognized compensation cost before tax on employee stock options $ 112,000,000             $ 112,000,000            
Total unrecognized compensation cost before tax on employee stock RSUs $ 138,000,000             $ 138,000,000            
Share based compensation arrangements expected over weighted average period               2 years 6 months            
Dividends declared and paid               $ 0.00 0.85 $ 1.36        
Dividend mandatory convertible preferred shares $ 0             $ 0 $ 70          
2010 Long-Term Equity-Based Incentive Plan [Member]                            
Class of Stock [Line Items]                            
Number of shares exercisable                           70,000,000
2015 Long-Term Equity-Based Incentive Plan [Member]                            
Class of Stock [Line Items]                            
Number of shares exercisable     142,000,000   77,000,000           43,700,000      
Number of additional shares authorized     65,000,000   33,300,000                  
Board of Directors [Member]                            
Class of Stock [Line Items]                            
Stock repurchase program, authorized amount $ 0             $ 0         $ 3,000,000,000  
Stock repurchase program, remaining authorized repurchase amount $ 2,100,000,000             $ 2,100,000,000         $ 1,300,000,000  
Minimum [Member] | Board of Directors [Member]                            
Class of Stock [Line Items]                            
Stock repurchase program, authorized amount                       $ 1,700,000,000    
Maximum [Member] | Board of Directors [Member]                            
Class of Stock [Line Items]                            
Stock repurchase program, authorized amount                       $ 3,000,000,000